Adjuvant Chemotherapy for Brain Tumors Delivered via a Novel Intra-Cavity Moldable Polymer Matrix

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Rahman, Cheryl V ^a   Smith, Stuart J ^a   Morgan, Paul S ^b   Langmack, Keith A ^b   Clarke, Phil A ^a   Ritchie, Alison A ^a   Macarthur, Donald C ^c   Rose, Felicity R ^a   Shakesheff, Kevin M ^a   Grundy, Richard G ^a   Rahman, Ruman ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; ETOPOSIDE; MACROGOL; METHOTREXATE; POLYGLACTIN; POLYMER; TRICHOSTATIN A;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; BRAIN TUMOR; CELL GROWTH; CELL VIABILITY; CHEMICAL STRUCTURE; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENDOTHELIUM CELL; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOTHERAPY; SHEEP; SUSTAINED DRUG RELEASE;

ANIMALS; BRAIN NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; DRUG DELIVERY SYSTEMS; ETOPOSIDE; HUMANS; LACTIC ACID; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, NUDE; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; SHEEP; TOMOGRAPHY, X-RAY COMPUTED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885393403     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077435     Document Type: Article

References (45)

1. Grundy RG, Wilne SA, Weston CL, (2007) Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study (vol 8, pg696, 2007). Lancet Oncol 8: 761-761. doi:10.1016/S1470-2045(07)70256-5.
2. Wilne S, Collier J, Kennedy C, Koller K, Grundy R, et al. (2007) Presentation of childhood CNS tumours: a systematic review 3 and meta-analysis. Lancet Oncol 8: 685-695. doi:10.1016/S1470-2045(07)70207-3. PubMed: 17644483.
3. Wolff JE, Brown R, Rytting M, Vats T, Bingham R, et al. (2010) Targeted personalized therapy for pediatric patients with refractory brain tumors. Neuro-Oncology 12: II89-II89.
4. Price SJ, Jena R, Burnet NG, Hutchinson PJ, Dean AF, et al. (2006) Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: An image-guided biopsy study. AJNR Am J Neuroradiol 27: 1969-1974. PubMed: 17032877.
5. Stummer W, Meinel T, Sabel M, Schackert G, (2008) Preliminary analysis from an observational study combining maximal resection and concomitant radiochemotherapy using temozolomide in glioblastoma multiforme. Neuro-Oncology 10: 1092-1092.
6. Wright KD, Gajjar A, (2009) New chemotherapy strategies and biological agents in the treatment of childhood ependymoma. Childs Nerv Syst 25: 1275-1282. doi:10.1007/s00381-009-0809-7. PubMed: 19212772.
7. Jang SH, Wientjes MG, Lu D, Au JLS, (2003) Drug delivery and transport to solid tumors. Pharm Res 20: 1337-1350. doi:10.1023/A:1025785505977. PubMed: 14567626.
8. Elstad NL, Fowers KD, (2009) OncoGel (ReGel/paclitaxel)- Clinical applications for a novel paclitaxel delivery system. Adv Drug Deliv Rev 61: 785-794. doi:10.1016/j.addr.2009.04.010. PubMed: 19422870.
9. Hadjipanayis CG, Machaidze R, Kaluzova M, Wang L, Schuette AJ, et al. (2010) EGFRvIII Antibody-Conjugated Iron Oxide Nanoparticles for Magnetic Resonance Imaging-Guided Convection-Enhanced Delivery and Targeted Therapy of Glioblastoma. Cancer Res 70: 6303-6312. doi:10.1158/0008-5472.CAN-10-1022. PubMed: 20647323.
10. Kim S, Nishimoto SK, Bumgardner JD, Haggard WO, Gaber MW, et al. (2010) A chitosan/beta-glycerophosphate thermo-sensitive gel for the delivery of ellagic acid for the treatment of brain cancer. Biomaterials 31: 4157-4166. doi:10.1016/j.biomaterials.2010.01.139. PubMed: 20185170.
11. Moses MA, Brem H, Langer R, (2003) Advancing the field of drug delivery: Taking aim at cancer. Cancer Cell 4: 337-341. doi:10.1016/S1535-6108(03)00276-9. PubMed: 14667500.
12. Ong BYS, Ranganath SH, Lee LY, Lu F, Lee H-S, et al. (2009) Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme. Biomaterials 30: 3189-3196. doi:10.1016/j.biomaterials.2009.02.030. PubMed: 19285718.
13. Petri B, Bootz A, Khalansky A, Hekmatara T, Müller R, et al. (2007) Chemotherapy of brain turnour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: Revisiting the role of surfactants. J Control Release 117: 51-58. doi:10.1016/j.jconrel.2006.10.015. PubMed: 17150277.
14. Ranganath SH, Fu Y, Arifin DY, Kee I, Zheng L, et al. (2010) The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice. Biomaterials 31: 5199-5207. doi:10.1016/j.biomaterials.2010.03.002. PubMed: 20350766.
15. Ranganath SH, Kee I, Krantz WB, Chow PK-H, Wang C-H, (2009) Hydrogel Matrix Entrapping PLGA-Paclitaxel Microspheres: Drug Delivery with Near Zero-Order Release and Implantability Advantages for Malignant Brain Tumour Chemotherapy. Pharm Res 26: 2101-2114. doi:10.1007/s11095-009-9922-2. PubMed: 19543956.
16. Tyler B, Fowers KD, Li KW, Recinos VR, Caplan JM, et al. (2010) A thermal gel depot for local delivery of paclitaxel to treat experimental brain tumors in rats Laboratory investigation. J Neurosurg 113: 210-217. doi:10.3171/2009.11.JNS08162. PubMed: 20001591.
17. Zentner GM, Rathi R, Shih C, McRea JC, Seo MH, et al. (2001) Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release 72: 203-215. doi:10.1016/S0168-3659(01)00276-0. PubMed: 11389999.
18. Bagley CA, Bookland MJ, Pindrik JA, Ozmen T, Gokaslan ZL, et al. (2007) Local delivery of OncoGel delays paresis in rat metastatic spinal tumor model. J Neurosurg-Spine 7: 194-198. doi:10.3171/SPI-07/08/194. PubMed: 17688059.
19. DuVall GA, Tarabar D, Seidel RH, Elstad NL, Fowers KD, (2009) Phase 2: a dose-escalation study of OncoGel (ReGel/paclitaxel), a controlled-release formulation of paclitaxel, as adjunctive local therapy to external-beam radiation in patients with inoperable esophageal cancer. Anti Cancer Drugs 20: 89-95. doi:10.1097/CAD.0b013e3283222c12. PubMed: 19209024.
20. Brem S, Tyler B, Li K, Pradilla G, Legnani F, et al. (2007) Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol 60: 643-650. doi:10.1007/s00280-006-0407-2. PubMed: 17256133.
21. Duffner PK, (2004) Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist 10: 293-310. doi:10.1097/01.nrl.0000144287.35993.96. PubMed: 15518596.
22. Brem H, Ewend MG, Piantadosi S, Greenhoot J, Burger PC, et al. (1995) The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: Phase I trial. J Neuro Oncol 26: 111-123. doi:10.1007/BF01060217. PubMed: 8787853.
23. Menei P, Metellus P, Parot-Schinkel E, Loiseau H, Capelle L, et al. (2010) Biodegradable Carmustine Wafers (Gliadel) Alone or in Combination with Chemoradiotherapy: The French Experience. Ann Surg Oncol 17: 1740-1746. doi:10.1245/s10434-010-1081-5. PubMed: 20443147.
24. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, et al. (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology 5: 79-88. doi:10.1215/15228517-5-2-79. PubMed: 12672279.
25. Fleming AB, Saltzman WM, (2002) Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 41: 403-419. doi:10.2165/00003088-200241060-00002. PubMed: 12074689.
26. Dhillon A, Schneider P, Kuhn G, Reinwald Y, White LJ, et al. (2011) Analysis of sintered polymer scaffolds using concomitant synchrotron computed tomography and in situ mechanical testing. J Mater Sci_Mater Med 22: 2599-2605. doi:10.1007/s10856-011-4443-z. PubMed: 21909640.
27. Gould TW, Birchall JP, Mallick AS, Alliston T, Lustig LR, et al. (2013) Development of a porous poly(DL-lactic acid-co-glycolic acid)-based scaffold for mastoid air-cell regeneration. Laryngoscope. PubMed: 23670365.
28. Rahman CV, Kuhn G, White LJ, Kirby GT, Varghese OP, et al. (2013) PLGA/PEG-hydrogel composite scaffolds with controllable mechanical properties. J Biomed Mater Res B Appl Biomater 101: 648-655. PubMed: 23359448.
29. Rahman CV, Ben-David D, Dhillon A, Kuhn G, Gould TW, et al. (2012) Controlled release of BMP-2 from a sintered polymer scaffold enhances bone repair in a mouse calvarial defect model. J Tissue Eng Regen Med.
30. Athanasiou KA, Niederauer GG, Agrawal CM, (1996) Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid polyglycolic acid copolymers. Biomaterials 17: 93-102. doi:10.1016/0142-9612(96)85754-1. PubMed: 8624401.
31. Anderson JM, Shive MS, (1997) Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 28: 5-24. doi:10.1016/S0169-409X(97)00048-3. PubMed: 10837562.
32. Langer R, (1998) Drug delivery and targeting. Nature 392: 5-10. doi:10.1038/32001. PubMed: 9579855.
33. Higaki M, Ishihara T, Izumo N, Takatsu M, Mizushima Y, (2005) Treatment of experimental arthritis with poly(D, L-lactic/glycolic acid) nanoparticles encapsulating betamethasone sodium phosphate. Ann Rheum Dis 64: 1132-1136. doi:10.1136/ard.2004.030759. PubMed: 15695536.
34. Bjugstad KB, Redmond DE Jr., Lampe KJ, Kern DS, Sladek JR Jr., et al. (2008) Biocompatibility of PEG-based hydrogels in primate brain. Cell Transplant 17: 409-415. PubMed: 18522243.
35. Emerich DF, Tracy MA, Ward KL, Figueiredo M, Qian RL, et al. (1999) Biocompatibility of poly (DL-lactide-co-glycolide) microspheres implanted into the brain. Cell Transplant 8: 47-58. PubMed: 10338275.
36. Brem H, Gabikian P, (2001) Biodegradable polymer implants to treat brain tumors. J Control Release 74: 63-67. doi:10.1016/S0168-3659(01)00311-X. PubMed: 11489483.
37. Zhang Y-H, Zhang H, Liu J-m, Yue Z-J, (2011) Temozolomide/PLGA microparticles: a new protocol for treatment of glioma in rats. Med Oncol 28: 901-906. doi:10.1007/s12032-010-9531-2. PubMed: 20396980.
38. Kasperczyk J, Stoklosa K, Dobrzynski P, Stepien K, Kaczmarczyk B, et al. (2009) Designing bioresorbable polyester matrices for controlled doxorubicin release in glioma therapy. Int J Pharm 382: 124-129. doi:10.1016/j.ijpharm.2009.08.022. PubMed: 19715746.
39. Missirlis D, Kawamura R, Tirelli N, Hubbell JA, (2006) Doxorubicin encapsulation and diffusional release from stable, polymeric, hydrogel nanoparticles. Eur J Pharm Sci 29: 120-129. doi:10.1002/jps.3030290308. PubMed: 16904301.
40. Tang BC, Fu J, Watkins DN, Hanes J, (2010) Enhanced efficacy of local etoposide delivery by poly(ether-anhydride) particles against small cell lung cancer in vivo. Biomaterials 31: 339-344. doi:10.1016/j.biomaterials.2009.09.033. PubMed: 19796810.
41. Trapani A, Denora N, Iacobellis G, Sitterberg J, Bakowsky U, et al. (2011) Methotrexate-loaded chitosan- and glycolchitosan-based nanoparticles: a promising strategy for the administration of the anticancer drug to brain tumors. AAPS PharmSciTech 12: 1302-1311. doi:10.1208/s12249-011-9695-x. PubMed: 21948322.
42. Domb AJ, Rock M, Perkin C, Yipchuck G, Broxup B, et al. (1995) Excretion of a radiolabelled anticancer biodegradable polymeric implant from the rabbit brain. Biomaterials 16: 1069-1072. doi:10.1016/0142-9612(95)98902-Q. PubMed: 8519927.
43. Rahman R, Osteso-Ibanez T, Hirst RA, Levesley J, Kilday J-P, et al. (2010) Histone Deacetylase Inhibition Attenuates Cell Growth with Associated Telomerase Inhibition in High-Grade Childhood Brain Tumor Cells. Mol Cancer Ther 9: 2568-2581. PubMed: 20643785.
44. Fredenberg S, Wahlgren M, Reslow M, Axelsson A, (2011) The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems-A review. Int J Pharm 415: 34-52. PubMed: 21640806.
45. Urbinati G, Marsaud V, Plassat V, Fattal E, Lesieur S, et al. (2010) Liposomes loaded with histone deacetylase inhibitors for breast cancer therapy. Int J Pharm 397: 184-193. PubMed: 20603204.